ERCC1 and non-small cell lung carcinoma: In NSCLC, overexpression of excision repair cross-complementation group 1 (ERCC1) has been strongly associated with resistance to cisplatin, making NER a critical contributor to chemoresistance and a potential therapeutic target [22].